In support of the above findings, enhanced antitumor activity was seen when combining the NAMPT inhibitor MV87 and an anti-PD1 antibody compared to the single therapies in a fibrosarcoma model [156]. The gene discussed is NAMPT; the disease is fibrosarcoma.